
How Mohs surgeons utilize prognostic testing for high-risk cutaneous squamous cell carcinoma (SCC): a clinical impact study

Sarah T. Arron, MD, PhD¹; Alison L. Fitzgerald, PhD²; Jennifer J. Siegel, PhD²; Briana Rackley, PhD²; Sarah J. Kurley, PhD²; Brent Moody, MD³ ¹Peninsula Dermatology, Burlingame, CA, USA; ²Castle Biosciences, Inc., Friendswood, TX, USA; ³Skin Cancer Surgery Center, Nashville, TN

Synopsis

- > Of the 1.8 million annually diagnosed SCC cases, more than 95% are cured by surgery; however, an average of 5% progress to metastasis, with up to 2.1% dying from the disease.¹⁻³ > A SCC patient's likelihood for poor outcomes governs management decisions regarding a
- multitude of treatment modalities.
- > The 40-gene expression profile (40-GEP) test has been validated to stratify primary SCC patients having one or more clinicopathologic risk factors into three biological risk groups (Low = Class 1; Moderate = Class 2A; High = Class 2B) based on risk for regional, nodal, or distant metastasis (Figure 1). ^{4,5}
- > Clinical validity studies have shown an improvement to risk stratification of high-risk SCC patients when compared to staging systems. ^{4,5}
- > When 40-GEP test results are incorporated into a clinician's initial risk assessment, clinical utility studies have demonstrated the ability of the test to personalize patient management plans in a risk-aligned manner. ⁵⁻⁹



Objective

> As Mohs surgeons are a clinical specialty likely to see high-risk SCC patients frequently, a clinical impact study was performed to determine how patient management decisions are impacted by their use of the 40-GEP test.

Methods

- > An anonymous survey was distributed to current American College of Mohs Surgery (ACMS) members. The study consisted of demographic questions, familiarity with and use of NCCN guidelines, AJCC-8 staging, BWH staging, and the 40-GEP.
- Participants (n=39) were provided with background on the validation of the 40-GEP test, then evaluated the use of risk factors for the assessment of SCC patients within their practice and which were concerning enough to warrant the use of the 40-GEP.
- Participants were presented with a high-risk SCC patient vignette and asked for their risk assessment and treatment approaches pre- and post-40-GEP results.

Results

> Demographics of the n=39 Mohs surgeons who participated in the study are shown in **Table 1**. The distribution of study participants usage of National Comprehensive Cancer Network (NCCN) guidelines and staging systems for risk assessment, along with their familiarity with GEP testing for SCC are shown in **Figure 2**.

Results


5% CI)	Overall Event Rate	
97.2%)	6.6%	
86.5%)	20.0%	
'3.3%)	52.2%	
88.9%)	15.0%	

- 40-GEP.
- indicated an increased risk of metastasis.

Table 1. Demographics			
Years in practice	(%)	Institution	
1-10 years	46	Academic cen	
11-20 years	38	Multi-specialty g	
		Other private pra	
21-30 years	8	Hospital base	
>30 years	8	other	

Following NCCN guidelines





* American Joint Committee on Cancer Staging Manual, 8th edition; **Brigham and Women's Hospital staging system

Ranking	Clinicopathologic risk fac
5	Depth >6mm or invasion beyond subcutant
5	Perineural involvement (Tumor cells within t
	nerve lying deeper than the dermis or ≥ 0.1 r
5	Lymphatic or vascular involvement*
5	Neurologic symptoms
4	Poor differentiation*
4	Immunosuppression
4	Tumor diameter >4cm any location*
4	Desmoplastic SCC*
3	Tumor at site of prior radiation therapy
3	Histologic features (acantholytic, adenosqua
3	Rapidly growing tumor
3	Recurrent
3	Perineural involvement (Tumor cells within t
	nerve ≤0.1mm)
3	Tumor diameter ≥2cm - <4cm on the trunk,
* Indicates N	CCN defined very high-risk factor

References

- 1. Rogers et al. JAMA Derm. 2015
- 2. skincancer.org, Skin Cancer Foundation 3. Schmults et al. JAMA Derm 2013
- 5. Ibrahim, et al. Future Oncol. 2021
- 6. Teplitz, et al. J Drugs Dermatol. 2019

Disclosures

- > JJS, SJK, ALF, AP, BR are employees and shareholders of Castle Biosciences, Inc. > STA is a consultant for Castle Biosciences, Inc.

4. Wysong, et al. J Am Acad Dermatol. 2027

'. Litchman, et al. CMRO. 2020 8. Arron, *et al.* J Drugs Dermatol. 2022

9. Hooper, *et al*. Cancer Invest. 2022



40-GEP results guide Mohs surgeons to make risk-aligned management plans and increase their confidence in these decisions. Overall, the 40-GEP can focus treatment options in the most riskappropriate manner, allowing for an optimization of healthcare resources and improved patient outcomes.